Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dexcom (DXCM) Free Cash Flow (2016 - 2025)

Dexcom (DXCM) has disclosed Free Cash Flow for 16 consecutive years, with $192.1 million as the latest value for Q4 2025.

  • On a quarterly basis, Free Cash Flow rose 8.65% to $192.1 million in Q4 2025 year-over-year; TTM through Dec 2025 was $1.1 billion, a 70.79% increase, with the full-year FY2025 number at $1.1 billion, up 70.79% from a year prior.
  • Free Cash Flow was $192.1 million for Q4 2025 at Dexcom, down from $579.4 million in the prior quarter.
  • In the past five years, Free Cash Flow ranged from a high of $579.4 million in Q3 2025 to a low of -$71.9 million in Q1 2021.
  • A 5-year average of $128.9 million and a median of $114.0 million in 2023 define the central range for Free Cash Flow.
  • Peak YoY movement for Free Cash Flow: crashed 141.29% in 2021, then skyrocketed 556.17% in 2025.
  • Dexcom's Free Cash Flow stood at $25.6 million in 2021, then surged by 169.53% to $69.0 million in 2022, then rose by 17.54% to $81.1 million in 2023, then skyrocketed by 118.0% to $176.8 million in 2024, then grew by 8.65% to $192.1 million in 2025.
  • Per Business Quant, the three most recent readings for DXCM's Free Cash Flow are $192.1 million (Q4 2025), $579.4 million (Q3 2025), and $208.9 million (Q2 2025).